Published in Expert Opin Investig Drugs on February 20, 2012
PET radiopharmaceuticals for imaging integrin expression: tracers in clinical studies and recent developments. Biomed Res Int (2014) 0.98
Angiogenesis-related pathways in the pathogenesis of ovarian cancer. Int J Mol Sci (2013) 0.93
Cancer stem cells: the 'heartbeat' of gastric cancer. J Gastroenterol (2012) 0.88
New therapeutic targets for cancer bone metastasis. Trends Pharmacol Sci (2015) 0.86
Monitoring vascular normalization induced by antiangiogenic treatment with (18)F-fluoromisonidazole-PET. Mol Oncol (2015) 0.84
Pazopanib and HDAC inhibitors interact to kill sarcoma cells. Cancer Biol Ther (2014) 0.82
Quantitative phosphoproteomics analysis reveals broad regulatory role of heparan sulfate on endothelial signaling. Mol Cell Proteomics (2013) 0.81
The Notch ligand Delta-like 4 (DLL4) as a target in angiogenesis-based cancer therapy? Contemp Oncol (Pozn) (2013) 0.81
H-CRRETAWAC-OH, a lead structure for the development of radiotracer targeting integrin α5β1? Biomed Res Int (2014) 0.78
Angiogenic neovessels promote tissue hypoxia. Proc Natl Acad Sci U S A (2016) 0.75
Expressions and Clinical Significances of Angiopoietin-1, Angiopoietin-2, and Tie-2 Receptor in Patients With Colorectal Cancer. Ann Coloproctol (2017) 0.75
Abnormalities in alternative splicing of angiogenesis-related genes and their role in HIV-related cancers. HIV AIDS (Auckl) (2017) 0.75
Tumor-secreted anterior gradient-2 binds to VEGF and FGF2 and enhances their activities by promoting their homodimerization. Oncogene (2017) 0.75
Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst (2008) 6.13
Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst (2005) 3.64
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol (2008) 2.82
Synthesis of some pyrazole derivatives and preliminary investigation of their affinity binding to P-glycoprotein. Bioorg Med Chem Lett (2005) 2.80
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol (2009) 2.80
Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol (2008) 2.56
Concern Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci U S A (2003) 2.52
Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res (2005) 2.21
Postoperative pain after conventional laparoscopy and laparoendoscopic single site surgery (LESS) for benign adnexal disease: a randomized trial. Fertil Steril (2011) 2.04
Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. Eur J Cancer (2010) 2.03
Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol (2004) 1.95
Quality of life and emotional distress in early stage and locally advanced cervical cancer patients: a prospective, longitudinal study. Gynecol Oncol (2011) 1.71
Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study. Oncology (2007) 1.70
Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res (2006) 1.67
Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. Blood (2006) 1.60
Role for granulocyte colony-stimulating factor in the generation of human T regulatory type 1 cells. Blood (2002) 1.57
Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin Cancer Res (2011) 1.53
Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival. Gynecol Oncol (2005) 1.52
Risk of postoperative pelvic abscess in major gynecologic oncology surgery: one-year single-institution experience. Ann Surg Oncol (2010) 1.50
Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer. Eur J Cancer (2013) 1.48
A prospective study of laparoscopy versus minilaparotomy in the treatment of uterine myomas. J Minim Invasive Gynecol (2005) 1.48
Mutations of an intronic repeat induce impaired MRE11 expression in primary human cancer with microsatellite instability. Oncogene (2004) 1.46
Minilaparotomy in early stage endometrial cancer: an alternative to standard and laparoscopic treatment. Gynecol Oncol (2002) 1.45
Laparoendoscopic single-site surgery (LESS) for ovarian cyst enucleation: report of first 3 cases. Fertil Steril (2009) 1.44
Functional properties of cells obtained from human cord blood CD34+ stem cells and mouse cardiac myocytes in coculture. Am J Physiol Heart Circ Physiol (2008) 1.42
Semiquantitative RT-PCR analysis to assess the expression levels of multiple transcripts from the same sample. Biol Proced Online (2001) 1.40
Incidence and risk factors for clinical failure of uterine leiomyoma embolization. Obstet Gynecol (2012) 1.39
Some criticism about postoperative pain after adnexal surgery performed by single-port versus standard laparoscopy. Fertil Steril (2012) 1.39
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol (2011) 1.36
Myoendothelial differentiation of human umbilical cord blood-derived stem cells in ischemic limb tissues. Circ Res (2003) 1.32
Local-regional staging of endometrial carcinoma: role of MR imaging in surgical planning. Radiology (2004) 1.30
Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3' flanking region. Gene (2007) 1.29
Granulocyte colony-stimulating factor promotes the generation of regulatory DC through induction of IL-10 and IFN-alpha. Eur J Immunol (2004) 1.29
Targeting CD133 antigen in cancer. Expert Opin Ther Targets (2009) 1.26
Syphilis Infection during pregnancy: fetal risks and clinical management. Infect Dis Obstet Gynecol (2012) 1.25
CD133 antigen expression in ovarian cancer. BMC Cancer (2009) 1.23
Neuropilin-1 expression identifies a subset of regulatory T cells in human lymph nodes that is modulated by preoperative chemoradiation therapy in cervical cancer. Immunology (2007) 1.22
The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance. Cancer Res (2005) 1.20
Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance. Mol Pharmacol (2003) 1.20
Erythropoietin exerts anti-apoptotic effects on rat microglial cells in vitro. Eur J Neurosci (2002) 1.20
A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann Surg Oncol (2006) 1.19
BRCA1-related malignancies in a family presenting with von Recklinghausen's disease. Gynecol Oncol (2002) 1.19
MiR-200c and HuR in ovarian cancer. BMC Cancer (2013) 1.18
Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors. Clin Cancer Res (2009) 1.17
Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer. J Cell Physiol (2012) 1.15
Laparoendoscopic single-site surgery for the treatment of benign adnexal disease: a prospective trial. Diagn Ther Endosc (2010) 1.14
Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res (2009) 1.13
Novel health economic evaluation of a vaccination strategy to prevent HPV-related diseases: the BEST study. Med Care (2012) 1.12
Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma. Am J Obstet Gynecol (2008) 1.12
Molecular mechanisms of patupilone resistance. Cancer Res (2008) 1.11
Pseudo-Meigs' syndrome associated with malignant struma ovarii: a case report. Gynecol Oncol (2004) 1.10
Laparoscopic surgical management of localized recurrent ovarian cancer: a single-institution experience. Surg Endosc (2014) 1.10
Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer (2011) 1.09
Cell cycle genes in ovarian cancer: steps toward earlier diagnosis and novel therapies. Clin Cancer Res (2004) 1.08
Non-surgical management of uterine fibroids. Hum Reprod Update (2008) 1.08
HMGA1 protein over-expression is a frequent feature of epithelial ovarian carcinomas. Carcinogenesis (2003) 1.07
Stereotactic radiotherapy in recurrent gynecological cancer: a case series. Oncol Rep (2009) 1.06
HuR regulates beta-tubulin isotype expression in ovarian cancer. Cancer Res (2010) 1.04
Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer: a pilot study. Gynecol Oncol (2005) 1.04
Trichostatin A up-regulates p73 and induces Bax-dependent apoptosis in cisplatin-resistant ovarian cancer cells. Mol Cancer Ther (2008) 1.04
Assay for apoptosis using the mitochondrial probes, Rhodamine123 and 10-N-nonyl acridine orange. Nat Protoc (2007) 1.04
Clinical performance of human papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix. J Clin Microbiol (2009) 1.04
Gender influences the class III and V β-tubulin ability to predict poor outcome in colorectal cancer. Clin Cancer Res (2012) 1.04
Circulating and thymic CD4 CD25 T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment. Immunology (2005) 1.03
Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer. Cancer Immunol Immunother (2009) 1.02
Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer. Cancer Chemother Pharmacol (2009) 1.01
Late tonsil metastases from renal cell cancer: a case report. Tumori (2009) 1.01
Phase I-II studies on accelerated IMRT in breast carcinoma: technical comparison and acute toxicity in 332 patients. Radiother Oncol (2008) 1.01
Total laparoendoscopic single-site surgery (LESS) hysterectomy in low-risk early endometrial cancer: a pilot study. Surg Endosc (2011) 1.00
Conservative surgical management of stage IA endometrial carcinoma for fertility preservation. Fertil Steril (2009) 1.00
Excisional cone as fertility-sparing treatment in early-stage cervical cancer. Fertil Steril (2010) 1.00
Looking at drug resistance mechanisms for microtubule interacting drugs: does TUBB3 work? Curr Cancer Drug Targets (2007) 0.99
Laparoscopic colorectal resection for bowel endometriosis: feasibility, complications, and clinical outcome. Arch Surg (2009) 0.99
Perioperative morbidity and mortality in elderly gynecological oncological patients (>/= 70 Years) by the American Society of Anesthesiologists physical status classes. Ann Surg Oncol (2004) 0.98
Cyclooxygenase-2 expression in endometrial carcinoma: correlation with clinicopathologic parameters and clinical outcome. Cancer (2002) 0.98
Laparoscopic, minilaparoscopic and single-port hysterectomy: perioperative outcomes. Surg Endosc (2012) 0.98
Comparative proteomic analysis of paclitaxel sensitive A2780 epithelial ovarian cancer cell line and its resistant counterpart A2780TC1 by 2D-DIGE: the role of ERp57. J Proteome Res (2009) 0.98
Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis. Apoptosis (2007) 0.97
βIII-Tubulin: biomarker of taxane resistance or drug target? Expert Opin Ther Targets (2013) 0.96
A prospective randomized study of laparoscopy and minilaparotomy in the management of benign adnexal masses. Hum Reprod (2004) 0.96